

Henry N Ginsberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4360513/publications.pdf>

Version: 2024-02-01

276
papers

40,608
citations

4658

85
h-index

2509

196
g-index

302
all docs

302
docs citations

302
times ranked

38531
citing authors

#	ARTICLE	IF	CITATIONS
1	Haptoglobin Phenotype Modifies the Effect of Fenofibrate on Risk of Coronary Event: ACCORD Lipid Trial. <i>Diabetes Care</i> , 2022, 45, 241-250.	8.6	6
2	LDL-C calculated by Friedewald, Martin-Hopkins, or NIH equation 2 versus beta-quantification: pooled alirocumab trials. <i>Journal of Lipid Research</i> , 2022, 63, 100148.	4.2	23
3	Dyrk1b promotes hepatic lipogenesis by bypassing canonical insulin signaling and directly activating mTORC2 in mice. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	20
4	The year in cardiovascular medicine 2021: dyslipidaemia. <i>European Heart Journal</i> , 2022, , .	2.2	9
5	TCF7L2 transcriptionally regulates <i>Fgf15</i> to maintain bile acid and lipid homeostasis through gut-liver crosstalk. <i>FASEB Journal</i> , 2022, 36, e22185.	0.5	3
6	Efficacy and Safety of K-877 (Pemafibrate), a Selective PPAR α Modulator, in European Patients on Statin Therapy. <i>Diabetes Care</i> , 2022, 45, 898-908.	8.6	17
7	Effect of Fenofibrate Therapy on Laser Treatment for Diabetic Retinopathy: A Meta-Analysis of Randomized Controlled Trials. <i>Diabetes Care</i> , 2022, 45, e1-e2.	8.6	6
8	Complex regulation of fatty liver disease. <i>Science</i> , 2022, 376, 247-248.	12.6	4
9	ApoB SURFs a Ride from the ER to the Golgi. <i>Cell Metabolism</i> , 2021, 33, 231-233.	16.2	18
10	Effect of Apabetalone on Cardiovascular Events in Diabetes, CKD, and Recent Acute Coronary Syndrome. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 705-716.	4.5	36
11	Nonalcohol fatty liver disease: balancing supply and utilization of triglycerides. <i>Current Opinion in Lipidology</i> , 2021, 32, 200-206.	2.7	10
12	Relationship of Plasma ApolipoproteinC3 with Plasma Lipoprotein(a). <i>FASEB Journal</i> , 2021, 35, .	0.5	0
13	Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial. <i>Cardiovascular Diabetology</i> , 2021, 20, 125.	6.8	11
14	Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1703-1715.	2.6	15
15	Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society. <i>European Heart Journal</i> , 2021, 42, 4791-4806.	2.2	303
16	Potential contribution of haemoconcentration to changes in lipid variables with empagliflozin in patients with type 2 diabetes: A post hoc analysis of pooled data from four phase 3 randomized clinical trials. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2763-2774.	4.4	4
17	Patients with raised Lipoprotein(a) are committed to being involved in clinical trials to develop a treatment to lower Lp(a): results of a survey distributed via the Lipoprotein(a) Foundation.. <i>Journal of Clinical Lipidology</i> , 2021, 15, e17.	1.5	1
18	Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. <i>Lancet Diabetes and Endocrinology</i> , the, 2020, 8, 50-67.	11.4	114

#	ARTICLE	IF	CITATIONS
19	Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial. <i>Circulation</i> , 2020, 141, 624-636.	1.6	155
20	Clinical review on triglycerides. <i>European Heart Journal</i> , 2020, 41, 99-109c.	2.2	286
21	Hypertriglyceridemia—Causes, Significance, and Approaches to Therapy. <i>Frontiers in Endocrinology</i> , 2020, 11, 616.	3.5	29
22	Reply. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2996-2997.	2.8	0
23	Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 3613-3682.	3.6	63
24	The Type and Amount of Dietary Fat Affect Plasma Factor VIIc, Fibrinogen, and PAI-1 in Healthy Individuals and Individuals at High Cardiovascular Disease Risk: 2 Randomized Controlled Trials. <i>Journal of Nutrition</i> , 2020, 150, 2089-2100.	2.9	4
25	<i>PPARA</i> Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD-Lipid. <i>Diabetes</i> , 2020, 69, 771-783.	0.6	28
26	Remnants of the Triglyceride-Rich Lipoproteins, Diabetes, and Cardiovascular Disease. <i>Diabetes</i> , 2020, 69, 508-516.	0.6	126
27	Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1565.	7.4	103
28	Engineering Liver Microtissues for Disease Modeling and Regenerative Medicine. <i>Advanced Functional Materials</i> , 2020, 30, 1909553.	14.9	28
29	Haptoglobin Phenotype Modifies the Influence of Intensive Glycemic Control on Cardiovascular Outcomes. <i>Journal of the American College of Cardiology</i> , 2020, 75, 512-521.	2.8	26
30	Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. <i>European Heart Journal</i> , 2020, 41, 2313-2330.	2.2	776
31	Diabetes and Dyslipidemia. <i>Endocrinology</i> , 2020, , 51-70.	0.1	0
32	Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control. <i>Atherosclerosis</i> , 2019, 288, 85-93.	0.8	16
33	Life is complicated: so is apoCIII. <i>Journal of Lipid Research</i> , 2019, 60, 1347-1349.	4.2	6
34	Evolocumab Treatment of Hypercholesterolemia in OSLER-1. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2147-2149.	2.8	4
35	Association of Triglyceride-Lowering <i>LPL</i> Variants and LDL-C—Lowering <i>LDLR</i> Variants With Risk of Coronary Heart Disease. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 364.	7.4	460
36	Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials. <i>Atherosclerosis</i> , 2019, 288, 194-202.	0.8	56

#	ARTICLE	IF	CITATIONS
37	Residual vascular risk in diabetes – Will the SPPARM alpha concept hold the key?. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2019, 13, 2723-2725.	3.6	4
38	Selective Trafficking of Fatty Acids in the Liver: Add Them2 to the List of Influencers. <i>Hepatology</i> , 2019, 70, 462-464.	7.3	1
39	Diabetes and Dyslipidemia. <i>Endocrinology</i> , 2019, , 1-20.	0.1	0
40	Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia. <i>Cardiovascular Drugs and Therapy</i> , 2019, 33, 69-76.	2.6	11
41	Effects of <i>APOC3</i> Heterozygous Deficiency on Plasma Lipid and Lipoprotein Metabolism. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 63-72.	2.4	61
42	Nuclear envelope-localized torsinA-LAP1 complex regulates hepatic VLDL secretion and steatosis. <i>Journal of Clinical Investigation</i> , 2019, 129, 4885-4900.	8.2	52
43	Is APOC3 the driver of cardiovascular disease in people with type I diabetes mellitus?. <i>Journal of Clinical Investigation</i> , 2019, 129, 4074-4076.	8.2	5
44	Diabetes and Dyslipidemia. <i>Endocrinology</i> , 2019, , 1-20.	0.1	0
45	Diabetes and Dyslipidemia. <i>Endocrinology</i> , 2019, , 1-20.	0.1	0
46	Predicting the Effect of Fenofibrate on Cardiovascular Risk for Individual Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2018, 41, 1244-1250.	8.6	16
47	Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1632-1641.	4.4	15
48	No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data. <i>European Heart Journal</i> , 2018, 39, 374-381.	2.2	57
49	NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis. <i>Journal of the American College of Cardiology</i> , 2018, 71, 177-192.	2.8	337
50	Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. <i>European Heart Journal</i> , 2018, 39, 2526-2539.	2.2	262
51	Î³-Secretase Inhibition Lowers Plasma Triglyceride-Rich Lipoproteins by Stabilizing the LDL Receptor. <i>Cell Metabolism</i> , 2018, 27, 816-827.e4.	16.2	18
52	Genetic Variants in <i>HSD17B3</i> , <i>SMAD3</i> , and <i>IPO11</i> Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 712-721.	4.7	30
53	Advanced Glycation End Products, Oxidation Products, and Incident Cardiovascular Events in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2018, 41, 570-576.	8.6	87
54	Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. <i>American Heart Journal</i> , 2018, 206, 80-93.	2.7	276

#	ARTICLE	IF	CITATIONS
55	Effects of mipomersen, an apolipoprotein B100 antisense, on lipoprotein (a) metabolism in healthy subjects. <i>Journal of Lipid Research</i> , 2018, 59, 2397-2402.	4.2	43
56	Lower On-Treatment Low-Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials. <i>Journal of the American Heart Association</i> , 2018, 7, e009221.	3.7	14
57	Efficacy and Safety of Alirocumab in Individuals with Diabetes Mellitus: Pooled Analyses from Five Placebo-Controlled Phase 3 Studies. <i>Diabetes Therapy</i> , 2018, 9, 1317-1334.	2.5	21
58	Diabetes and Dislipidemia. <i>Endocrinology</i> , 2018, , 1-20.	0.1	0
59	Progress and perspectives in plant sterol and plant stanol research. <i>Nutrition Reviews</i> , 2018, 76, 725-746.	5.8	54
60	FoxO transcription factors are required for hepatic HDL cholesterol clearance. <i>Journal of Clinical Investigation</i> , 2018, 128, 1615-1626.	8.2	18
61	Diabetes and Dislipidemia. <i>Endocrinology</i> , 2018, , 51-70.	0.1	0
62	Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes. <i>Current Cardiology Reports</i> , 2017, 19, 7.	2.9	42
63	Postprandial lipemia and the risk of coronary heart disease and stroke: the Atherosclerosis Risk in Communities (ARIC) Study. <i>BMJ Open Diabetes Research and Care</i> , 2017, 5, e000335.	2.8	16
64	Chronic alcohol consumption decreases brown adipose tissue mass and disrupts thermoregulation: a possible role for altered retinoid signaling. <i>Scientific Reports</i> , 2017, 7, 43474.	3.3	16
65	Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. <i>European Heart Journal</i> , 2017, 38, 2459-2472.	2.2	2,292
66	LOWER ON-TREATMENT LOW-DENSITY LIPOPROTEIN CHOLESTEROL IS ASSOCIATED WITH LOWER CARDIOVASCULAR RISK IN VERY HIGH RISK PATIENTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: ANALYSES FROM THE ODYSSEY TRIALS. <i>Journal of the American College of Cardiology</i> , 2017, 69, 55.	2.8	1
67	Effects of CETP inhibition with anacetrapib on metabolism of VLDL-TG and plasma apolipoproteins C-II, C-III, and E. <i>Journal of Lipid Research</i> , 2017, 58, 1214-1220.	4.2	18
68	Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes. <i>JAMA Cardiology</i> , 2017, 2, 370.	6.1	136
69	Normalization of Hepatic Homeostasis in the Npc1 Mouse Model of Niemann-Pick Type C Disease Treated with the Histone Deacetylase Inhibitor Vorinostat. <i>Journal of Biological Chemistry</i> , 2017, 292, 4395-4410.	3.4	28
70	Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans. <i>Circulation</i> , 2017, 135, 352-362.	1.6	185
71	Increase in apolipoprotein-A2 Levels is associated with lower cardiovascular risk in the accord lipid trial. <i>Atherosclerosis</i> , 2017, 263, e43.	0.8	0
72	CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 1770-1775.	2.4	71

#	ARTICLE	IF	CITATIONS
73	The metabolism of lipoprotein (a): an ever-evolving story. <i>Journal of Lipid Research</i> , 2017, 58, 1756-1764.	4.2	67
74	Lipidomic and Proteomic Predictors of Drastic Reductions of HDL in the ACCORD Lipid Trial. <i>Journal of Clinical Lipidology</i> , 2017, 11, 792.	1.5	0
75	Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 947.	7.4	247
76	Personalized glucose forecasting for type 2 diabetes using data assimilation. <i>PLoS Computational Biology</i> , 2017, 13, e1005232.	3.2	74
77	Abstract 21171: Combinatorial Aso-Mediated Knockdown of ApoB and DGAT2 Inhibits Both VLDL Secretion and High Fat Diet Induced Hepatic Steatosis. <i>Circulation</i> , 2017, 136, .	1.6	0
78	Type 1 Deiodinase Regulates ApoA-I Gene Expression and ApoA-I Synthesis Independent of Thyroid Hormone Signaling. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 1356-1366.	2.4	18
79	Inverse Relationship Between Major Adverse Cardiovascular Events and non-High-Density Lipoprotein Cholesterol and Apolipoprotein B in Phase 3 Trials of Alirocumab. <i>Journal of Clinical Lipidology</i> , 2016, 10, 724.	1.5	0
80	Impaired postprandial lipemic response in chronic kidney disease. <i>Kidney International</i> , 2016, 90, 172-180.	5.2	14
81	No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies. <i>European Heart Journal</i> , 2016, 37, 2981-2989.	2.2	142
82	Lipid changes during basal insulin peglispro, insulin glargine, or <sc>NPH</sc> treatment in six <sc>IMAGINE</sc> trials. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 1089-1092.	4.4	15
83	Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160Âmg/dl or Higher. <i>Cardiovascular Drugs and Therapy</i> , 2016, 30, 473-483.	2.6	160
84	Efficacy and Safety of Alirocumab 150Âmg Every 4ÂWeeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	71
85	Reductions in Atherogenic Lipids and Major Cardiovascular Events. <i>Circulation</i> , 2016, 134, 1931-1943.	1.6	110
86	Complex effects of inhibiting hepatic apolipoprotein B100 synthesis in humans. <i>Science Translational Medicine</i> , 2016, 8, 323ra12.	12.4	27
87	Lipoprotein (a): Coming of Age at Last. <i>Journal of Lipid Research</i> , 2016, 57, 336-339.	4.2	21
88	Effect of Recombinant Human Growth Hormone and Rosiglitazone for HIV-Associated Abdominal Fat Accumulation on Adiponectin and other Markers of Inflammation. <i>HIV Clinical Trials</i> , 2016, 17, 55-62.	2.0	6
89	Targeted Proteomics Identifies Paraoxonase/Arylesterase 1 (PON1) and Apolipoprotein Cs as Potential Risk Factors for Hypoalphalipoproteinemia in Diabetic Subjects Treated with Fenofibrate and Rosiglitazone. <i>Molecular and Cellular Proteomics</i> , 2016, 15, 1083-1093.	3.8	23
90	Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 994-1002.	2.4	32

#	ARTICLE	IF	CITATIONS
91	Inhibition of apolipoprotein B synthesis stimulates endoplasmic reticulum autophagy that prevents steatosis. <i>Journal of Clinical Investigation</i> , 2016, 126, 3852-3867.	8.2	38
92	PCSK9 inhibitors and cardiovascular disease. <i>Current Opinion in Lipidology</i> , 2015, 26, 511-520.	2.7	56
93	Statin-associated muscle symptoms: impact on statin therapyâ€”European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. <i>European Heart Journal</i> , 2015, 36, 1012-1022.	2.2	1,024
94	Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. <i>European Heart Journal</i> , 2015, 36, 2425-2437.	2.2	644
95	Nonstatin Low-Density Lipoproteinâ€”Lowering Therapy and Cardiovascular Risk Reductionâ€”Statement From the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 2269-2280.	2.4	58
96	ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. <i>European Heart Journal</i> , 2015, 36, ehv370.	2.2	395
97	Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects. <i>Journal of Clinical Investigation</i> , 2015, 125, 2510-2522.	8.2	67
98	Abstract 129: Effects of a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor, Alirocumab, on Lipid and Lipoprotein Metabolism in Normal Subjects. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, .	2.4	0
99	Abstract 18390: Effects of a Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) Inhibitor, Alirocumab, on Lipid and Lipoprotein Metabolism in Healthy Subjects. <i>Circulation</i> , 2015, 132, .	1.6	1
100	Gerald M. Reaven, MD: Demonstration of the Central Role of Insulin Resistance in Type 2 Diabetes and Cardiovascular Disease. <i>Diabetes Care</i> , 2014, 37, 1178-1181.	8.6	42
101	Cardiomyocyte-specific Loss of Diacylglycerol Acyltransferase 1 (DGAT1) Reproduces the Abnormalities in Lipids Found in Severe Heart Failure. <i>Journal of Biological Chemistry</i> , 2014, 289, 29881-29891.	3.4	60
102	Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. <i>European Heart Journal</i> , 2014, 35, 2146-2157.	2.2	835
103	Genetic dissection of retinoid esterification and accumulation in the liver and adipose tissue. <i>Journal of Lipid Research</i> , 2014, 55, 104-114.	4.2	41
104	Cognitive Function and Brain Structure in Persons With Type 2 Diabetes Mellitus After Intensive Lowering of Blood Pressure and Lipid Levels. <i>JAMA Internal Medicine</i> , 2014, 174, 324.	5.1	142
105	Static and turnover kinetic measurement of protein biomarkers involved in triglyceride metabolism including apoB48 and apoA5 by LC/MS/MS. <i>Journal of Lipid Research</i> , 2014, 55, 1179-1187.	4.2	17
106	The Combined Hyperlipidemia Caused by Impaired Wnt-LRP6 Signaling Is Reversed by Wnt3a Rescue. <i>Cell Metabolism</i> , 2014, 19, 209-220.	16.2	95
107	Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. <i>Atherosclerosis</i> , 2014, 232, 346-360.	0.8	419
108	Autophagy and cardiometabolic risk factors. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2014, 15, 307-315.	5.7	17

#	ARTICLE	IF	CITATIONS
109	Monthly haemostatic factor variability in women and men. <i>European Journal of Clinical Investigation</i> , 2014, 44, 309-318.	3.4	4
110	Effect of Alirocumab, a Monoclonal Proprotein Convertase Subtilisin/Kexin 9 Antibody, on Lipoprotein(a) Concentrations (a Pooled Analysis of 150Åmg Every Two Weeks Dosing from Phase 2) Tj ETQq0 0 0rgBT /Overrbck 10 Tf	11.4	2
111	Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized Phase 3 trial. <i>International Journal of Cardiology</i> , 2014, 176, 55-61.	1.7	229
112	Practical Immunoaffinity-Enrichment LC-MS for Measuring Protein Kinetics of Low-Abundance Proteins. <i>Clinical Chemistry</i> , 2014, 60, 1217-1224.	3.2	31
113	The 2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol. <i>Circulation Research</i> , 2014, 114, 761-764.	4.5	17
114	Effects of Randomization to Intensive Glucose Control on Adverse Events, Cardiovascular Disease, and Mortality in Older Versus Younger Adults in the ACCORD Trial. <i>Diabetes Care</i> , 2014, 37, 634-643.	8.6	104
115	Paradoxical Reduction in HDL-C With Fenofibrate and Thiazolidinedione Therapy in Type 2 Diabetes: The ACCORD Lipid Trial. <i>Diabetes Care</i> , 2014, 37, 686-693.	8.6	19
116	Treatment of severe hypertriglyceridaemia â€œ Authors' reply. <i>Lancet Diabetes and Endocrinology</i> ,the, 2014, 2, 860-861.	11.4	2
117	The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. <i>Lancet Diabetes and Endocrinology</i> ,the, 2014, 2, 655-666.	11.4	473
118	The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice. <i>Atherosclerosis Supplements</i> , 2014, 15, 1-15.	1.2	83
119	Abstract 628: Hepatic Insulin Signaling Regulates ApoA-I Gene Expression Through the Type I Deiodinase.. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, .	2.4	0
120	Abstract 634: Treatment with Mipomersen Reduces Levels of ApoB-Containing Lipoproteins by Increasing Fractional Removal of VLDL and LDL-apoB Without Reducing VLDL-apob Secretion. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, .	2.4	1
121	Statins in cardiometabolic disease: what makes pitavastatin different?. <i>Cardiovascular Diabetology</i> , 2013, 12, S1.	6.8	17
122	Inhibition of Notch uncouples Akt activation from hepatic lipid accumulation by decreasing mTorc1 stability. <i>Nature Medicine</i> , 2013, 19, 1054-1060.	30.7	126
123	Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. <i>European Heart Journal</i> , 2013, 34, 3478-3490.	2.2	2,132
124	Niacin. <i>Current Opinion in Lipidology</i> , 2013, 24, 475-479.	2.7	23
125	Measurement of apo(a) kinetics in human subjects using a microfluidic device with tandem mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2013, 27, 1294-1302.	1.5	31
126	Effect of Combination Therapy With Fenofibrate and Simvastatin on Postprandial Lipemia in the ACCORD Lipid Trial. <i>Diabetes Care</i> , 2013, 36, 422-428.	8.6	43

#	ARTICLE	IF	CITATIONS
127	Recombinant Human Growth Hormone and Rosiglitazone for Abdominal Fat Accumulation in HIV-Infected Patients with Insulin Resistance: A Randomized, Double-Blind, Placebo-Controlled, Factorial Trial. <i>PLoS ONE</i> , 2013, 8, e61160.	2.5	14
128	Apolipoprotein B Secretion Is Regulated by Hepatic Triglyceride, and Not Insulin, in a Model of Increased Hepatic Insulin Signaling. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, 236-246.	2.4	35
129	Reversibility of Fenofibrate Therapy-Induced Renal Function Impairment in ACCORD Type 2 Diabetic Participants. <i>Diabetes Care</i> , 2012, 35, 1008-1014.	8.6	114
130	Intestinal DGAT1 deficiency reduces postprandial triglyceride and retinyl ester excursions by inhibiting chylomicron secretion and delaying gastric emptying. <i>Journal of Lipid Research</i> , 2012, 53, 2364-2379.	4.2	55
131	Guidelines for the use and interpretation of assays for monitoring autophagy. <i>Autophagy</i> , 2012, 8, 445-544.	9.1	3,122
132	CCR5 Plays a Critical Role in Obesity-Induced Adipose Tissue Inflammation and Insulin Resistance by Regulating Both Macrophage Recruitment and M1/M2 Status. <i>Diabetes</i> , 2012, 61, 1680-1690.	0.6	235
133	Antisense reduction of 11 β -hydroxysteroid dehydrogenase type 1 enhances energy expenditure and insulin sensitivity independent of food intake in C57BL/6J mice on a Western-type diet. <i>Metabolism: Clinical and Experimental</i> , 2012, 61, 823-835.	3.4	10
134	Activation of ER stress and mTORC1 suppresses hepatic sortilin-1 levels in obese mice. <i>Journal of Clinical Investigation</i> , 2012, 122, 1677-1687.	8.2	96
135	Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. <i>European Heart Journal</i> , 2011, 32, 1345-1361.	2.2	993
136	Triglycerides and Cardiovascular Disease. <i>Circulation</i> , 2011, 123, 2292-2333.	1.6	1,511
137	Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes. <i>New England Journal of Medicine</i> , 2011, 364, 818-828.	27.0	901
138	Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance. <i>Trends in Endocrinology and Metabolism</i> , 2011, 22, 353-363.	7.1	293
139	Role of fibrates in cardiovascular disease prevention, the ACCORD-Lipid perspective. <i>Current Opinion in Lipidology</i> , 2011, 22, 55-61.	2.7	41
140	The ACCORD-Lipid study: implications for treatment of dyslipidemia in Type 2 diabetes mellitus. <i>Clinical Lipidology</i> , 2011, 6, 9-20.	0.4	52
141	Improved diabetic control in advanced heart failure patients treated with left ventricular assist devices. <i>European Journal of Heart Failure</i> , 2011, 13, 195-199.	7.1	58
142	Combination therapy with statin and fibrate in patients with dyslipidemia associated with insulin resistance, metabolic syndrome and type 2 diabetes mellitus. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 1429-1438.	1.8	16
143	DGAT1 deficiency decreases PPAR expression and does not lead to lipotoxicity in cardiac and skeletal muscle. <i>Journal of Lipid Research</i> , 2011, 52, 732-744.	4.2	75
144	Different fatty acids inhibit apoB100 secretion by different pathways: unique roles for ER stress, ceramide, and autophagy. <i>Journal of Lipid Research</i> , 2011, 52, 1636-1651.	4.2	70

#	ARTICLE	IF	CITATIONS
145	The ACCORD (Action to Control Cardiovascular Risk in Diabetes) Lipid Trial: What we learn from subgroup analyses. <i>Diabetes Care</i> , 2011, 34, S107-S108.	8.6	66
146	Apolipoprotein CIII. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 471-473.	2.4	63
147	Effects of antisense-mediated inhibition of 11 β -hydroxysteroid dehydrogenase type 1 on hepatic lipid metabolism. <i>Journal of Lipid Research</i> , 2011, 52, 971-981.	4.2	36
148	Development of Apolipoprotein B Antisense Molecules as a Therapy for Hyperlipidemia. <i>Current Atherosclerosis Reports</i> , 2010, 12, 58-65.	4.8	27
149	Endothelial function in individuals with coronary artery disease with and without type 2 diabetes mellitus. <i>Metabolism: Clinical and Experimental</i> , 2010, 59, 1365-1371.	3.4	20
150	Short Sleep Duration as a Risk Factor for Hypercholesterolemia: Analyses of the National Longitudinal Study of Adolescent Health. <i>Sleep</i> , 2010, 33, 956-961.	1.1	175
151	Lipoprotein(a) as a cardiovascular risk factor: current status. <i>European Heart Journal</i> , 2010, 31, 2844-2853.	2.2	1,392
152	C-C Chemokine Receptor 2 (CCR2) Regulates the Hepatic Recruitment of Myeloid Cells That Promote Obesity-Induced Hepatic Steatosis. <i>Diabetes</i> , 2010, 59, 916-925.	0.6	267
153	Targeting ApoB as a therapeutic approach for the treatment of dyslipidemia: the potential role of mipomersen. <i>Clinical Lipidology</i> , 2010, 5, 457-464.	0.4	5
154	Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. <i>New England Journal of Medicine</i> , 2010, 362, 1563-1574.	27.0	2,460
155	Measures of postprandial lipoproteins are not associated with coronary artery disease in patients with type 2 diabetes mellitus. <i>Journal of Lipid Research</i> , 2009, 50, 1901-1909.	4.2	18
156	The ever-expanding role of degradation in the regulation of apolipoprotein B metabolism. <i>Journal of Lipid Research</i> , 2009, 50, S162-S166.	4.2	138
157	Adipose tissue distribution after weight restoration and weight maintenance in women with anorexia nervosa. <i>American Journal of Clinical Nutrition</i> , 2009, 90, 1132-1137.	4.7	41
158	The Obesity, Metabolic Syndrome, and Type 2 Diabetes Mellitus Pandemic: Part I. Increased Cardiovascular Disease Risk and the Importance of Atherogenic Dyslipidemia in Persons With the Metabolic Syndrome and Type 2 Diabetes Mellitus. <i>Journal of the Cardiometabolic Syndrome</i> , 2009, 4, 113-119.	1.7	241
159	The Obesity, Metabolic Syndrome, and Type 2 Diabetes Mellitus Pandemic: II. Therapeutic Management of Atherogenic Dyslipidemia. <i>Journal of Clinical Hypertension</i> , 2009, 11, 520-527.	2.0	20
160	The Endocannabinoid System: Potential for Reducing Cardiometabolic Risk. <i>Obesity</i> , 2009, 17, 1821-1829.	3.0	9
161	Title page. <i>American Journal of Cardiology</i> , 2008, 102, i.	1.6	103
162	Relative Atherogenicity and Predictive Value of Non-HDL High-Density Lipoprotein Cholesterol for Coronary Heart Disease. <i>American Journal of Cardiology</i> , 2008, 101, 1003-1008.	1.6	96

#	ARTICLE	IF	CITATIONS
163	Effectiveness of Combined Statin Plus Omega-3 Fatty Acid Therapy for Mixed Dyslipidemia. <i>American Journal of Cardiology</i> , 2008, 102, 1040-1045.	1.6	62
164	The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia. <i>American Journal of Cardiology</i> , 2008, 102, 1K-34K.	1.6	371
165	Hepatic Insulin Resistance Is Sufficient to Produce Dyslipidemia and Susceptibility to Atherosclerosis. <i>Cell Metabolism</i> , 2008, 7, 125-134.	16.2	383
166	Effects of a 1,3-diacylglycerol oil-enriched diet on postprandial lipemia in people with insulin resistance. <i>Journal of Lipid Research</i> , 2008, 49, 670-678.	4.2	20
167	Kinetic Studies of the Metabolism of Rapidly Exchangeable Apolipoproteins May Leave Investigators and Readers With Exchangeable Results. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 1685-1686.	2.4	10
168	Inhibition of apolipoprotein B100 secretion by lipid-induced hepatic endoplasmic reticulum stress in rodents. <i>Journal of Clinical Investigation</i> , 2008, 118, 316-332.	8.2	320
169	Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus. <i>Circulation</i> , 2007, 115, 114-126.	1.6	634
170	Efficacy and tolerability of adding prescription Omega-3 fatty acids 4 g/d to Simvastatin 40 mg/d in hypertriglyceridemic patients: An 8-week, randomized, double-blind, placebo-controlled study. <i>Clinical Therapeutics</i> , 2007, 29, 1354-1367.	2.5	371
171	Effects of triacylglycerol and diacylglycerol oils on blood clearance, tissue uptake, and hepatic apolipoprotein B secretion in mice. <i>Journal of Lipid Research</i> , 2007, 48, 1108-1121.	4.2	18
172	Dietary 1,3-diacylglycerol protects against diet-induced obesity and insulin resistance. <i>Metabolism: Clinical and Experimental</i> , 2007, 56, 1566-1575.	3.4	22
173	Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus. <i>Diabetes Care</i> , 2007, 30, 162-172.	8.6	577
174	Evolution of the Lipid Trial Protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. <i>American Journal of Cardiology</i> , 2007, 99, S56-S67.	1.6	87
175	Lipoprotein metabolism in chronic renal insufficiency. <i>Pediatric Nephrology</i> , 2007, 22, 1095-1112.	1.7	67
176	Comparison of monounsaturated fat with carbohydrates as a replacement for saturated fat in subjects with a high metabolic risk profile: studies in the fasting and postprandial states. <i>American Journal of Clinical Nutrition</i> , 2007, 86, 1611-1620.	4.7	73
177	Diabetic Dyslipidemia. <i>Endocrinology and Metabolism Clinics of North America</i> , 2006, 35, 491-510.	3.2	187
178	Is the slippery slope from steatosis to steatohepatitis paved with triglyceride or cholesterol?. <i>Cell Metabolism</i> , 2006, 4, 179-181.	16.2	41
179	Metabolic Syndrome: Focus on Dyslipidemia. <i>Obesity</i> , 2006, 14, 41S-49S.	3.0	162
180	Cholesterol Management: Targeting a Lower Low-Density Lipoprotein Cholesterol Concentration Increases Adult Treatment Panel-III Goal Attainment. <i>American Journal of Cardiology</i> , 2006, 97, 1667-1669.	1.6	6

#	ARTICLE	IF	CITATIONS
181	The JLR opens up its heart (and liver, fat, muscle) to patient-oriented research. <i>Journal of Lipid Research</i> , 2006, 47, 1605-1606.	4.2	0
182	Niacin in the metabolic syndrome: more risk than benefit?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2006, 2, 300-301.	2.8	20
183	REVIEW: Efficacy and Mechanisms of Action of Statins in the Treatment of Diabetic Dyslipidemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 383-392.	3.6	132
184	Aberrant Hepatic Expression of PPAR β Stimulates Hepatic Lipogenesis in a Mouse Model of Obesity, Insulin Resistance, Dyslipidemia, and Hepatic Steatosis. <i>Journal of Biological Chemistry</i> , 2006, 281, 37603-37615.	3.4	134
185	Translocation Efficiency of Apolipoprotein B Is Determined by the Presence of β -Sheet Domains, Not Pause Transfer Sequences. <i>Journal of Biological Chemistry</i> , 2006, 281, 27063-27071.	3.4	22
186	Cholesterol-Lowering Benefits of Oat-Containing Cereal in Hispanic Americans. <i>Journal of the American Dietetic Association</i> , 2005, 105, 967-970.	1.1	100
187	Regulation of Plasma Triglycerides in Insulin Resistance and Diabetes. <i>Archives of Medical Research</i> , 2005, 36, 232-240.	3.3	420
188	Postprandial response to a physiologic caloric load in HIV-positive patients receiving protease inhibitor-based or nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. <i>American Journal of Clinical Nutrition</i> , 2005, 82, 146-154.	4.7	4
189	Treatment with high-dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemia. <i>Journal of Lipid Research</i> , 2005, 46, 2735-2744.	4.2	34
190	Whole-body Insulin Resistance in the Absence of Obesity in FVB Mice With Overexpression of Dgat1 in Adipose Tissue. <i>Diabetes</i> , 2005, 54, 3379-3386.	0.6	45
191	Adipocyte Signaling and Lipid Homeostasis. <i>Circulation Research</i> , 2005, 96, 1042-1052.	4.5	314
192	Effects of the PPAR β agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. <i>Journal of Clinical Investigation</i> , 2005, 115, 1323-1332.	8.2	160
193	Effects of the PPAR β agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. <i>Journal of Clinical Investigation</i> , 2005, 115, 1323-1332.	8.2	95
194	Regulation of Hepatic Apolipoprotein B-lipoprotein Assembly and Secretion by the Availability of Fatty Acids. <i>Journal of Biological Chemistry</i> , 2004, 279, 19362-19374.	3.4	83
195	Overexpression of Human Diacylglycerol Acyltransferase 1, Acyl-CoA:Cholesterol Acyltransferase 1, or Acyl-CoA:Cholesterol Acyltransferase 2 Stimulates Secretion of Apolipoprotein B-containing Lipoproteins in McA-RH7777 Cells. <i>Journal of Biological Chemistry</i> , 2004, 279, 44938-44944.	3.4	81
196	The role of acyl-CoA:diacylglycerol acyltransferase (DGAT) in energy metabolism. <i>Annals of Medicine</i> , 2004, 36, 252-261.	3.8	65
197	Lipid peroxidation and oxidant stress regulate hepatic apolipoprotein B degradation and VLDL production. <i>Journal of Clinical Investigation</i> , 2004, 113, 1277-1287.	8.2	228
198	Treatment for patients with the metabolic syndrome. <i>American Journal of Cardiology</i> , 2003, 91, 29-39.	1.6	81

#	ARTICLE	IF	CITATIONS
199	Ovariectomy leads to increased insulin resistance in human apolipoprotein B transgenic mice lacking brown adipose tissue. <i>Metabolism: Clinical and Experimental</i> , 2003, 52, 659-661.	3.4	11
200	The Metabolic Syndrome: Targeting Dyslipidaemia to Reduce Coronary Risk. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2003, 10, 121-128.	2.8	22
201	Overexpression of the Tumor Autocrine Motility Factor Receptor Gp78, a Ubiquitin Protein Ligase, Results in Increased Ubiquitylation and Decreased Secretion of Apolipoprotein B100 in HepG2 Cells. <i>Journal of Biological Chemistry</i> , 2003, 278, 23984-23988.	3.4	107
202	The Conversion of ApoB100 Low Density Lipoprotein/High Density Lipoprotein Particles to ApoB100 Very Low Density Lipoproteins in Response to Oleic Acid Occurs in the Endoplasmic Reticulum and Not in the Golgi in McA RH7777 Cells. <i>Journal of Biological Chemistry</i> , 2003, 278, 42643-42651.	3.4	48
203	The metabolic syndrome: targeting dyslipidaemia to reduce coronary risk. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2003, 10, 121-8.	1.5	31
204	New Perspectives on Atherogenesis. <i>Circulation</i> , 2002, 106, 2137-2142.	1.6	227
205	Posttranscriptional Control of the Expression and Function of Diacylglycerol Acyltransferase-1 in Mouse Adipocytes. <i>Journal of Biological Chemistry</i> , 2002, 277, 50876-50884.	3.4	59
206	The Late Addition of Core Lipids to Nascent Apolipoprotein B100, Resulting in the Assembly and Secretion of Triglyceride-rich Lipoproteins, Is Independent of Both Microsomal Triglyceride Transfer Protein Activity and New Triglyceride Synthesis. <i>Journal of Biological Chemistry</i> , 2002, 277, 4413-4421.	3.4	59
207	Complexity in the Secretory Pathway: The Assembly and Secretion of Apolipoprotein B-containing Lipoproteins. <i>Journal of Biological Chemistry</i> , 2002, 277, 17377-17380.	3.4	398
208	Dyslipidemia in pediatric renal disease: epidemiology, pathophysiology, and management. <i>Current Opinion in Pediatrics</i> , 2002, 14, 197-204.	2.0	54
209	Reply to 'Dyslipidemia due to retroviral protease inhibitors'. <i>Nature Medicine</i> , 2002, 8, 308-309.	30.7	5
210	Variation in the Human ApoB Signal Peptide Modulates ApoB17 Translocation. <i>Biochemical and Biophysical Research Communications</i> , 2001, 283, 149-157.	2.1	11
211	Diabetes and dyslipidemia. <i>Current Diabetes Reports</i> , 2001, 1, 93-95.	4.2	11
212	HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: A potential mechanism for protease inhibitor-induced hyperlipidemia. <i>Nature Medicine</i> , 2001, 7, 1327-1331.	30.7	237
213	Hypertriglyceridemia: new insights and new approaches to pharmacologic therapy. <i>American Journal of Cardiology</i> , 2001, 87, 1174-1180.	1.6	58
214	Microsomal Triglyceride Transfer Protein Binding and Lipid Transfer Activities Are Independent of Each Other, but Both Are Required for Secretion of Apolipoprotein B Lipoproteins from Liver Cells. <i>Journal of Biological Chemistry</i> , 2001, 276, 28606-28612.	3.4	40
215	Co-translational Interactions of Apoprotein B with the Ribosome and Translocon during Lipoprotein Assembly or Targeting to the Proteasome. <i>Journal of Biological Chemistry</i> , 2001, 276, 541-550.	3.4	79
216	Post-transcriptional Stimulation of the Assembly and Secretion of Triglyceride-rich Apolipoprotein B Lipoproteins in a Mouse with Selective Deficiency of Brown Adipose Tissue, Obesity, and Insulin Resistance. <i>Journal of Biological Chemistry</i> , 2001, 276, 46064-46072.	3.4	70

#	ARTICLE	IF	CITATIONS
217	Long-term cholesterol-lowering effects of psyllium as an adjunct to diet therapy in the treatment of hypercholesterolemia. <i>American Journal of Clinical Nutrition</i> , 2000, 71, 1433-1438.	4.7	141
218	Predictors of postprandial triacylglycerol response in children: the Columbia University Biomarkers Study. <i>American Journal of Clinical Nutrition</i> , 2000, 72, 1119-1127.	4.7	29
219	The Amino-terminal Domain of Apolipoprotein B Does Not Undergo Retrograde Translocation from the Endoplasmic Reticulum to the Cytosol. <i>Journal of Biological Chemistry</i> , 2000, 275, 32003-32010.	3.4	38
220	Acute Elevations of Plasma Asymmetric Dimethylarginine and Impaired Endothelial Function in Response to a High-Fat Meal in Patients With Type 2 Diabetes. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000, 20, 2039-2044.	2.4	205
221	Insulin resistance and cardiovascular disease. <i>Journal of Clinical Investigation</i> , 2000, 106, 453-458.	8.2	997
222	Inhibition of Translocation of Nascent Apolipoprotein B across the Endoplasmic Reticulum Membrane Is Associated with Selective Inhibition of the Synthesis of Apolipoprotein B. <i>Journal of Biological Chemistry</i> , 2000, 275, 27399-27405.	3.4	19
223	HDL-subpopulation patterns in response to reductions in dietary total and saturated fat intakes in healthy subjects. <i>American Journal of Clinical Nutrition</i> , 1999, 70, 992-1000.	4.7	62
224	Identification and treatment of hypertriglyceridemia as a risk factor for coronary heart disease. <i>Current Cardiology Reports</i> , 1999, 1, 233-237.	2.9	15
225	Effects of Statins on Triglyceride Metabolism. <i>American Journal of Cardiology</i> , 1998, 81, 32B-35B.	1.6	83
226	Regulated Co-translational Ubiquitination of Apolipoprotein B100. <i>Journal of Biological Chemistry</i> , 1998, 273, 24649-24653.	3.4	134
227	Effects of Reducing Dietary Saturated Fatty Acids on Plasma Lipids and Lipoproteins in Healthy Subjects. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1998, 18, 441-449.	2.4	255
228	Translocation Efficiency, Susceptibility to Proteasomal Degradation, and Lipid Responsiveness of Apolipoprotein B Are Determined by the Presence of I ² Sheet Domains. <i>Journal of Biological Chemistry</i> , 1998, 273, 35216-35221.	3.4	41
229	Lipid metabolism: new approaches to old problems. <i>Current Opinion in Lipidology</i> , 1998, 9, 185-187.	2.7	0
230	Is Hypertriglyceridemia a Risk Factor for Atherosclerotic Cardiovascular Disease? A Simple Question with a Complicated Answer. <i>Annals of Internal Medicine</i> , 1997, 126, 912.	3.9	43
231	I.P.267 LPL-93G promoter mutation influences both baseline plasma triglycerides and postprandial response in black and hispanics. <i>Atherosclerosis</i> , 1997, 134, 72-73.	0.8	0
232	The Degradation of Apolipoprotein B100 Is Mediated by the Ubiquitin-proteasome Pathway and Involves Heat Shock Protein 70. <i>Journal of Biological Chemistry</i> , 1997, 272, 20427-20434.	3.4	257
233	A Two-site Model for ApoB Degradation in HepG2 Cells. <i>Journal of Biological Chemistry</i> , 1997, 272, 11575-11580.	3.4	80
234	ApoE Genotype Does Not Predict Lipid Response to Changes in Dietary Saturated Fatty Acids in a Heterogeneous Normolipidemic Population. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 17, 2914-2923.	2.4	33

#	ARTICLE	IF	CITATIONS
235	Demonstration of Biphasic Effects of Docosahexaenoic Acid on Apolipoprotein B Secretion in HepG2 Cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 17, 3347-3355.	2.4	20
236	ROLE OF LIPID SYNTHESIS, CHAPERONE PROTEINS AND PROTEASOMES IN THE ASSEMBLY AND SECRETION OF APOPROTEIN B-CONTAINING LIPOPROTEINS FROM CULTURED LIVER CELLS. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1997, 24, a29-a32.	1.9	46
237	EFFECT OF PRAVASTATIN IN THE TREATMENT OF PATIENTS WITH TYPE III HYPERLIPOPROTEINEMIA. <i>American Journal of Therapeutics</i> , 1996, 3, 755-762.	0.9	7
238	Evidence That a Rapidly Turning Over Protein, Normally Degraded by Proteasomes, Regulates hsp72 Gene Transcription in HepG2 Cells. <i>Journal of Biological Chemistry</i> , 1996, 271, 24769-24775.	3.4	72
239	Demonstration of a Physical Interaction between Microsomal Triglyceride Transfer Protein and Apolipoprotein B during the Assembly of ApoB-containing Lipoproteins. <i>Journal of Biological Chemistry</i> , 1996, 271, 10277-10281.	3.4	118
240	EDITORIAL REVIEW: Nutrition and therapeutics: where we are and where we should be going. <i>Current Opinion in Lipidology</i> , 1995, 6, 1-2.	2.7	4
241	Synthesis and secretion of apolipoprotein B from cultured liver cells. <i>Current Opinion in Lipidology</i> , 1995, 6, 275-280.	2.7	69
242	Low HDL Cholesterol: What Are the Prospects of Increasing It?. <i>Annals of Medicine</i> , 1995, 27, 283-284.	3.8	1
243	Update on the treatment of hypercholesterolemia, with a focus on hmgâ€œa reductase inhibitors and combination regimens. <i>Clinical Cardiology</i> , 1995, 18, 307-315.	1.8	12
244	Association of Postprandial Triglyceride and Retinyl Palmitate Responses With Newly Diagnosed Exercise-Induced Myocardial Ischemia in Middle-Aged Men and Women. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1995, 15, 1829-1838.	2.4	120
245	Increases in Dietary Cholesterol Are Associated With Modest Increases in Both LDL and HDL Cholesterol in Healthy Young Women. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1995, 15, 169-178.	2.4	86
246	Apoprotein B100, an Inefficiently Translocated Secretory Protein, Is Bound to the Cytosolic Chaperone, Heat Shock Protein 70. <i>Journal of Biological Chemistry</i> , 1995, 270, 25220-25224.	3.4	66
247	Lipoprotein metabolism and its relationship to atherosclerosis. <i>Medical Clinics of North America</i> , 1994, 78, 1-20.	2.5	99
248	Hepatic Synthesis of Lipoproteins and Apolipoproteins. <i>Seminars in Liver Disease</i> , 1992, 12, 364-372.	3.6	51
249	Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: Evidence for reduced assembly and secretion of triglyceride-rich lipoproteins. <i>Metabolism: Clinical and Experimental</i> , 1992, 41, 487-493.	3.4	96
250	Lipoprotein Physiology in Nondiabetic and Diabetic States: Relationship to Atherogenesis. <i>Diabetes Care</i> , 1991, 14, 839-855.	8.6	260
251	Reduction of Plasma Cholesterol Levels in Normal Men on an American Heart Association Step 1 Diet or a Step 1 Diet with Added Monounsaturated Fat. <i>New England Journal of Medicine</i> , 1990, 322, 574-579.	27.0	209
252	High density lipoprotein cholesterol is reduced in patients with sarcoidosis. <i>American Journal of Medicine</i> , 1989, 86, 376-378.	1.5	14

#	ARTICLE	IF	CITATIONS
253	Heterogeneity of apolipoprotein A-I turnover in subjects with reduced concentrations of plasma high density lipoprotein cholesterol. <i>Metabolism: Clinical and Experimental</i> , 1988, 37, 614-617.	3.4	70
254	Abnormalities in lipoprotein metabolism in Gaucher type 1 disease. <i>Metabolism: Clinical and Experimental</i> , 1988, 37, 240-245.	3.4	32
255	Changes in lipoprotein kinetics during therapy with fenofibrate and other fibric acid derivatives. <i>American Journal of Medicine</i> , 1987, 83, 66-70.	1.5	59
256	Very low density lipoprotein metabolism in diabetes mellitus. <i>Diabetes/metabolism Reviews</i> , 1987, 3, 571-589.	0.3	41
257	Altered high density lipoprotein metabolism in patients with myeloproliferative disorders and hypocholesterolemia. <i>Metabolism: Clinical and Experimental</i> , 1986, 35, 878-882.	3.4	29
258	Isolation of apolipoprotein E-containing lipoproteins by immunoaffinity chromatography. <i>Methods in Enzymology</i> , 1986, 129, 186-198.	1.0	6
259	Kinetic analysis using specific radioactivity data. <i>Methods in Enzymology</i> , 1986, 129, 384-395.	1.0	18
260	Direct determination of apolipoprotein C-III specific activity using immunoaffinity chromatography. <i>Methods in Enzymology</i> , 1986, 129, 457-469.	1.0	2
261	Hypocholesterolemia and acute myelogenous leukemia: Association between disease activity and plasma low-density lipoprotein cholesterol concentrations. <i>Cancer</i> , 1986, 58, 1361-1365.	4.1	83
262	Changes in Plasma Lipids and Lipoproteins during Isotretinoin Therapy for Acne. <i>New England Journal of Medicine</i> , 1985, 313, 981-985.	27.0	206
263	Apo E-mediated uptake and degradation of normal very low density lipoproteins by human monocyte/macrophages: A saturable pathway distinct from the LDL receptor. <i>Biochemical and Biophysical Research Communications</i> , 1985, 126, 578-586.	2.1	48
264	Treatment of common lipoprotein disorders. <i>Progress in Cardiovascular Diseases</i> , 1984, 27, 1-20.	3.1	31
265	Reduced plasma concentrations of total, low density lipoprotein and high density lipoprotein cholesterol in patients with Gaucher type I disease. <i>Clinical Genetics</i> , 1984, 26, 109-116.	2.0	47
266	Hypocholesterolemia as a manifestation of disease activity in chronic myelocytic leukemia. <i>Cancer</i> , 1983, 51, 1428-1433.	4.1	34
267	Case Report: Transient Lipoprotein Lipase Deficiency with Hyperchylomicronemia. <i>American Journal of the Medical Sciences</i> , 1983, 286, 28-31.	1.1	11
268	Increased Low-Density-Lipoprotein Catabolism in Myeloproliferative Disorders. <i>Annals of Internal Medicine</i> , 1982, 96, 311.	3.9	41
269	Lipoprotein Metabolism during Acute Inhibition of Hepatic Triglyceride Lipase in the Cynomolgus Monkey. <i>Journal of Clinical Investigation</i> , 1982, 70, 1184-1192.	8.2	247
270	Characterization of hypocholesterolemia in myeloproliferative disease. <i>American Journal of Medicine</i> , 1981, 71, 595-602.	1.5	95

#	ARTICLE	IF	CITATIONS
271	Effect of a high carbohydrate diet on apoprotein-B catabolism in man. <i>Metabolism: Clinical and Experimental</i> , 1981, 30, 347-353.	3.4	75
272	The use of continuous insulin infusion for the peripartum management of pregnant diabetic women. <i>American Journal of Obstetrics and Gynecology</i> , 1978, 131, 861-864.	1.3	25
273	Investigation of insulin resistance during diabetic ketoacidosis: Role of counterregulatory substances and effect of insulin therapy. <i>Metabolism: Clinical and Experimental</i> , 1977, 26, 1135-1146.	3.4	48
274	Induction of Hypertriglyceridemia by a Low-Fat Diet. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1976, 42, 729-735.	3.6	103
275	Metabolic effects of increased caloric intake in man. <i>Metabolism: Clinical and Experimental</i> , 1975, 24, 495-503.	3.4	53
276	Moderate Ethanol Ingestion and Plasma Triglyceride Levels. <i>Annals of Internal Medicine</i> , 1974, 80, 143.	3.9	132